European regulators have granted Mauna Kea Technologies expanded CE mark approval for its Cellvizio confocal laser endomicroscopy device. Under the expanded approval, the platform can now be marketed for laparoscopic procedures. It had been previously approved for fine-needle aspiration procedures and use in the biliary and pancreatic ducts, urinary and respiratory systems and the gastrointestinal tract.
A 106-patient study presented at the annual Digestive Disease Week found that a diagnosis of Barrett's esophagus indefinite for dysplasia may develop into dysplasia or esophageal adenocarcinoma within a year of diagnosis. Researchers found that seven of the 87 patients who underwent endoscopies and biopsies within a year of diagnosis experienced disease progression.
U.S. and international experts recommended routine use of the confocal laser endomicroscopy system Cellvizio to improve diagnosis and management of Barrett's esophagus, colorectal lesions, biliary strictures and inflammatory bowel diseases. The experts also made recommendations on training and credentialing.
People with Barrett's esophagus have a higher risk of developing esophageal cancer but are not any more likely to die sooner than those with a normal esophagus, Mayo Clinic researchers reported at the ACG annual meeting. The study found 68% of Barrett's patients were still alive 10 years after diagnosis, which was comparable to a control group without the condition.
For some people, years of acid reflux can damage the lining of the esophagus and lead to a condition called Barrett's esophagus, Dr. Paul Donohue writes in his medical column. If left untreated, Barrett's esophagus can evolve into esophageal cancer.